肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

Clinical cancer res：Degarelix联合或不联合Cy/GVAX治疗高危局限性前列腺癌的效果

2020-03-15 MedSci原创 MedSci原创

前列腺癌环磷酰胺Degarelix
关注

既往研究表明，雄激素剥夺治疗(ADT)可促进前列腺癌的抗肿瘤免疫。基于疫苗的方法是否能增强这一效果仍不清楚

既往研究表明，雄激素剥夺治疗(ADT)可促进前列腺癌的抗肿瘤免疫。基于疫苗的方法是否能增强这一效果仍不清楚

研究人员开展了一项新辅助的随机化研究，以量化粒细胞-巨噬细胞集落刺激因子(GM-CSF)-分泌异基因细胞疫苗联合低剂量环磷酰胺(Cy/GVAX)+地加瑞克（degarelix）或地加瑞克治对计划进行根治性前列腺切除术的高危局限性前列腺腺癌患者的免疫效果。

与未进行治疗的对照相比，Cy/GVAX+地加瑞克和单用地加瑞克均可显著增加肿瘤中的CD8+ T细胞浸润和PD-L1的表达。但CD8+ T细胞浸润伴调节性T细胞(Treg)比例增加，提示适应性Treg抵抗可能会抑制ADT的免疫原性。虽然Cy/GVAX联合地加瑞克可以适度改善PSA的进展和下一次治疗的时间，并增加PD-L1的表达，但CD8 T细胞浸润与单独使用地加瑞克无差异。基因表达谱显示，与单用地加瑞克相比，Cy/GVAX联合地加瑞克可使巨噬细胞标记物CHIT1表达上调。

本研究结果表明，无论是否联合Cy/GVAX， ADT都可在前列腺肿瘤微环境中诱导复杂的免疫反应。些数据对ADT联合免疫治疗有重要意义。特别是，该研究发现ADT可增加CD8+ T细胞和Treg的数量，支持ADT与Treg耗竭剂联合治疗前列腺癌方案的发展。

原始出处：
 

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1924046, encodeId=73821924046ef, content=<a href='/topic/show?id=61d24e655df' target=_blank style='color:#2F92EE;'>#局限性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47655, encryptionId=61d24e655df, topicName=局限性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sat May 09 17:30:03 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460474, encodeId=9ef614604e4b0, content=<a href='/topic/show?id=ebf74e65779' target=_blank style='color:#2F92EE;'>#局限性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47657, encryptionId=ebf74e65779, topicName=局限性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8256335432, createdName=yang0212, createdTime=Tue Mar 17 07:30:03 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507708, encodeId=2d26150e70839, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Tue Mar 17 07:30:03 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380542, encodeId=33603805421c, content=新冠全球大爆发，当时在中国出现时，其他国家没重视吗？, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kGw5jg99bxLo3JvFSwO53KRlnpeV71YF9nhR1tRQHxASyfpaQ1OYpH94z7399OIkpUHmyhLQbJunNpGOfBnjJA/132, createdBy=bdee5289307, createdName=libra2778, createdTime=Mon Mar 16 04:19:14 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040680, encodeId=391c10406807e, content=前列腺癌相关研究，学习了，谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Mar 15 19:30:03 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047012, encodeId=8b16104e01294, content=疗效只是效果的众多方面之一，还要看对患者的获益，包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sun Mar 15 19:30:03 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380527, encodeId=7fd938052e0a, content=论团队, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/sL9VBZ1wX08pLbnNXBTnGAPaat7fkRukxXNMYNK4LzUWFibcvg7WRPme5Uy5mh1f5HW9qicG1etmDBGsqsrbg2yg/132, createdBy=9ce65310990, createdName=xcdnxj, createdTime=Sun Mar 15 19:14:31 CST 2020, time=2020-03-15, status=1, ipAttribution=)]
    2020-05-09 haouestc

    #局限性#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1924046, encodeId=73821924046ef, content=<a href='/topic/show?id=61d24e655df' target=_blank style='color:#2F92EE;'>#局限性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47655, encryptionId=61d24e655df, topicName=局限性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sat May 09 17:30:03 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460474, encodeId=9ef614604e4b0, content=<a href='/topic/show?id=ebf74e65779' target=_blank style='color:#2F92EE;'>#局限性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47657, encryptionId=ebf74e65779, topicName=局限性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8256335432, createdName=yang0212, createdTime=Tue Mar 17 07:30:03 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507708, encodeId=2d26150e70839, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Tue Mar 17 07:30:03 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380542, encodeId=33603805421c, content=新冠全球大爆发，当时在中国出现时，其他国家没重视吗？, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kGw5jg99bxLo3JvFSwO53KRlnpeV71YF9nhR1tRQHxASyfpaQ1OYpH94z7399OIkpUHmyhLQbJunNpGOfBnjJA/132, createdBy=bdee5289307, createdName=libra2778, createdTime=Mon Mar 16 04:19:14 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040680, encodeId=391c10406807e, content=前列腺癌相关研究，学习了，谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Mar 15 19:30:03 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047012, encodeId=8b16104e01294, content=疗效只是效果的众多方面之一，还要看对患者的获益，包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sun Mar 15 19:30:03 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380527, encodeId=7fd938052e0a, content=论团队, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/sL9VBZ1wX08pLbnNXBTnGAPaat7fkRukxXNMYNK4LzUWFibcvg7WRPme5Uy5mh1f5HW9qicG1etmDBGsqsrbg2yg/132, createdBy=9ce65310990, createdName=xcdnxj, createdTime=Sun Mar 15 19:14:31 CST 2020, time=2020-03-15, status=1, ipAttribution=)]
    2020-03-17 yang0212

    #局限性前列腺癌#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1924046, encodeId=73821924046ef, content=<a href='/topic/show?id=61d24e655df' target=_blank style='color:#2F92EE;'>#局限性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47655, encryptionId=61d24e655df, topicName=局限性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sat May 09 17:30:03 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460474, encodeId=9ef614604e4b0, content=<a href='/topic/show?id=ebf74e65779' target=_blank style='color:#2F92EE;'>#局限性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47657, encryptionId=ebf74e65779, topicName=局限性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8256335432, createdName=yang0212, createdTime=Tue Mar 17 07:30:03 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507708, encodeId=2d26150e70839, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Tue Mar 17 07:30:03 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380542, encodeId=33603805421c, content=新冠全球大爆发，当时在中国出现时，其他国家没重视吗？, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kGw5jg99bxLo3JvFSwO53KRlnpeV71YF9nhR1tRQHxASyfpaQ1OYpH94z7399OIkpUHmyhLQbJunNpGOfBnjJA/132, createdBy=bdee5289307, createdName=libra2778, createdTime=Mon Mar 16 04:19:14 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040680, encodeId=391c10406807e, content=前列腺癌相关研究，学习了，谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Mar 15 19:30:03 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047012, encodeId=8b16104e01294, content=疗效只是效果的众多方面之一，还要看对患者的获益，包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sun Mar 15 19:30:03 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380527, encodeId=7fd938052e0a, content=论团队, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/sL9VBZ1wX08pLbnNXBTnGAPaat7fkRukxXNMYNK4LzUWFibcvg7WRPme5Uy5mh1f5HW9qicG1etmDBGsqsrbg2yg/132, createdBy=9ce65310990, createdName=xcdnxj, createdTime=Sun Mar 15 19:14:31 CST 2020, time=2020-03-15, status=1, ipAttribution=)]
    2020-03-17 zll0628

    #clinical#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1924046, encodeId=73821924046ef, content=<a href='/topic/show?id=61d24e655df' target=_blank style='color:#2F92EE;'>#局限性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47655, encryptionId=61d24e655df, topicName=局限性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sat May 09 17:30:03 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460474, encodeId=9ef614604e4b0, content=<a href='/topic/show?id=ebf74e65779' target=_blank style='color:#2F92EE;'>#局限性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47657, encryptionId=ebf74e65779, topicName=局限性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8256335432, createdName=yang0212, createdTime=Tue Mar 17 07:30:03 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507708, encodeId=2d26150e70839, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Tue Mar 17 07:30:03 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380542, encodeId=33603805421c, content=新冠全球大爆发，当时在中国出现时，其他国家没重视吗？, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kGw5jg99bxLo3JvFSwO53KRlnpeV71YF9nhR1tRQHxASyfpaQ1OYpH94z7399OIkpUHmyhLQbJunNpGOfBnjJA/132, createdBy=bdee5289307, createdName=libra2778, createdTime=Mon Mar 16 04:19:14 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040680, encodeId=391c10406807e, content=前列腺癌相关研究，学习了，谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Mar 15 19:30:03 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047012, encodeId=8b16104e01294, content=疗效只是效果的众多方面之一，还要看对患者的获益，包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sun Mar 15 19:30:03 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380527, encodeId=7fd938052e0a, content=论团队, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/sL9VBZ1wX08pLbnNXBTnGAPaat7fkRukxXNMYNK4LzUWFibcvg7WRPme5Uy5mh1f5HW9qicG1etmDBGsqsrbg2yg/132, createdBy=9ce65310990, createdName=xcdnxj, createdTime=Sun Mar 15 19:14:31 CST 2020, time=2020-03-15, status=1, ipAttribution=)]
    2020-03-16 libra2778

    新冠全球大爆发，当时在中国出现时，其他国家没重视吗？

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1924046, encodeId=73821924046ef, content=<a href='/topic/show?id=61d24e655df' target=_blank style='color:#2F92EE;'>#局限性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47655, encryptionId=61d24e655df, topicName=局限性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sat May 09 17:30:03 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460474, encodeId=9ef614604e4b0, content=<a href='/topic/show?id=ebf74e65779' target=_blank style='color:#2F92EE;'>#局限性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47657, encryptionId=ebf74e65779, topicName=局限性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8256335432, createdName=yang0212, createdTime=Tue Mar 17 07:30:03 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507708, encodeId=2d26150e70839, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Tue Mar 17 07:30:03 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380542, encodeId=33603805421c, content=新冠全球大爆发，当时在中国出现时，其他国家没重视吗？, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kGw5jg99bxLo3JvFSwO53KRlnpeV71YF9nhR1tRQHxASyfpaQ1OYpH94z7399OIkpUHmyhLQbJunNpGOfBnjJA/132, createdBy=bdee5289307, createdName=libra2778, createdTime=Mon Mar 16 04:19:14 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040680, encodeId=391c10406807e, content=前列腺癌相关研究，学习了，谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Mar 15 19:30:03 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047012, encodeId=8b16104e01294, content=疗效只是效果的众多方面之一，还要看对患者的获益，包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sun Mar 15 19:30:03 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380527, encodeId=7fd938052e0a, content=论团队, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/sL9VBZ1wX08pLbnNXBTnGAPaat7fkRukxXNMYNK4LzUWFibcvg7WRPme5Uy5mh1f5HW9qicG1etmDBGsqsrbg2yg/132, createdBy=9ce65310990, createdName=xcdnxj, createdTime=Sun Mar 15 19:14:31 CST 2020, time=2020-03-15, status=1, ipAttribution=)]
    2020-03-15 misszhang

    前列腺癌相关研究，学习了，谢谢梅斯

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1924046, encodeId=73821924046ef, content=<a href='/topic/show?id=61d24e655df' target=_blank style='color:#2F92EE;'>#局限性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47655, encryptionId=61d24e655df, topicName=局限性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sat May 09 17:30:03 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460474, encodeId=9ef614604e4b0, content=<a href='/topic/show?id=ebf74e65779' target=_blank style='color:#2F92EE;'>#局限性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47657, encryptionId=ebf74e65779, topicName=局限性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8256335432, createdName=yang0212, createdTime=Tue Mar 17 07:30:03 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507708, encodeId=2d26150e70839, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Tue Mar 17 07:30:03 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380542, encodeId=33603805421c, content=新冠全球大爆发，当时在中国出现时，其他国家没重视吗？, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kGw5jg99bxLo3JvFSwO53KRlnpeV71YF9nhR1tRQHxASyfpaQ1OYpH94z7399OIkpUHmyhLQbJunNpGOfBnjJA/132, createdBy=bdee5289307, createdName=libra2778, createdTime=Mon Mar 16 04:19:14 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040680, encodeId=391c10406807e, content=前列腺癌相关研究，学习了，谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Mar 15 19:30:03 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047012, encodeId=8b16104e01294, content=疗效只是效果的众多方面之一，还要看对患者的获益，包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sun Mar 15 19:30:03 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380527, encodeId=7fd938052e0a, content=论团队, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/sL9VBZ1wX08pLbnNXBTnGAPaat7fkRukxXNMYNK4LzUWFibcvg7WRPme5Uy5mh1f5HW9qicG1etmDBGsqsrbg2yg/132, createdBy=9ce65310990, createdName=xcdnxj, createdTime=Sun Mar 15 19:14:31 CST 2020, time=2020-03-15, status=1, ipAttribution=)]
    2020-03-15 CHANGE

    疗效只是效果的众多方面之一，还要看对患者的获益，包括生活质量等因素共同决定效果的

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1924046, encodeId=73821924046ef, content=<a href='/topic/show?id=61d24e655df' target=_blank style='color:#2F92EE;'>#局限性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47655, encryptionId=61d24e655df, topicName=局限性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sat May 09 17:30:03 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460474, encodeId=9ef614604e4b0, content=<a href='/topic/show?id=ebf74e65779' target=_blank style='color:#2F92EE;'>#局限性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47657, encryptionId=ebf74e65779, topicName=局限性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8256335432, createdName=yang0212, createdTime=Tue Mar 17 07:30:03 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507708, encodeId=2d26150e70839, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ee59933733, createdName=zll0628, createdTime=Tue Mar 17 07:30:03 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380542, encodeId=33603805421c, content=新冠全球大爆发，当时在中国出现时，其他国家没重视吗？, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kGw5jg99bxLo3JvFSwO53KRlnpeV71YF9nhR1tRQHxASyfpaQ1OYpH94z7399OIkpUHmyhLQbJunNpGOfBnjJA/132, createdBy=bdee5289307, createdName=libra2778, createdTime=Mon Mar 16 04:19:14 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040680, encodeId=391c10406807e, content=前列腺癌相关研究，学习了，谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Mar 15 19:30:03 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047012, encodeId=8b16104e01294, content=疗效只是效果的众多方面之一，还要看对患者的获益，包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sun Mar 15 19:30:03 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380527, encodeId=7fd938052e0a, content=论团队, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/sL9VBZ1wX08pLbnNXBTnGAPaat7fkRukxXNMYNK4LzUWFibcvg7WRPme5Uy5mh1f5HW9qicG1etmDBGsqsrbg2yg/132, createdBy=9ce65310990, createdName=xcdnxj, createdTime=Sun Mar 15 19:14:31 CST 2020, time=2020-03-15, status=1, ipAttribution=)]
    2020-03-15 xcdnxj

    论团队

    0

相关资讯

NEJM：MRI靶向 vs系统活检用于前列腺病变检查

研究认为，MRI靶向前列腺活检联合系统活检可最大程度降低前列腺癌误诊风险

典型前列腺癌1例

老年男性，发现PSA升高半月

Oncogene：具有短聚谷氨酸尾巴的雄激素受体能够增强Wnt/β-连环蛋白介导的前列腺致瘤过程

人类雄激素受体（AR）聚谷氨酸（polyQ）尾巴的多样性表明了群体的异质性存在。非裔美国男性要比白种美国男性具有显著更高频率的短polyQ尾巴。polyQ尾巴的长度与前列腺癌风险、起始年龄和诊断时侵入情况呈负相关关系。Wnt信号的异常激活经常在晚期前列腺癌中发生，并且在非裔美国男性中富集雄激素和Wnt信号激活。最近，有研究人员在新建立的小鼠前列腺致瘤模型中评估了AR的异常表达情况，这些小鼠存在不同

J Clin Invest：NGS提早发现前列腺癌“指纹”，助力其诊断和治疗监测

导读：现有的前列腺特异性抗原测试不能很快识别癌症是否扩散，研究人员在血检中发现一种早期循环生物标志物，提高了识别的敏感度，可用于前列腺癌的诊断和治疗监测。

Prostate Cancer P D：转移去势抵抗性前列腺癌中雄激素受体状态和AR-null表型的基于免疫组化评估

基于分子和免疫组化的前列腺肿瘤分析阐释了在转移性疾病中雄激素受体（AR）基因和蛋白的高频变异。其中包括了转移去势抵抗性前列腺癌中的AR-null非神经内分泌表型，且对雄激素后踢信号抑制剂敏感度较弱。该AR-null非神经内分泌表型被认为与TP53和RB1变异相关。因此，有研究人员阐释了转移去势抵抗性前列腺癌分子情况与AR/P53/RB免疫组化的关系和相关的临床联系。研究包括了27个转移去势抵抗性前

Sci Rep：Survivin的亚细胞区室化与前列腺癌的恶化和预后相关

Survivin的亚细胞区室化在前列腺癌的生物学和预后中的作用仍旧未知。因此，有研究人员通过使用定量免疫组化在不少于3000个前列腺癌患者中调查了Survivin的亚细胞定位情况，并对公共数据库中的250名前列腺癌患者和健康捐赠者的转录组数据进行分析。研究发现，Survivin（BIRC5）基因表达在原发前列腺癌和转移中增加，但在复发和非复发前列腺癌中没有差异。Survivin免疫组化（IHC）染